Report Summary

ImmunoGen, Inc Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

ImmunoGen develops targeted anticancer biopharmaceuticals. The company’s tumor-activated prodrug (TAP) technology uses tumor-targeting antibodies to deliver a cell-killing agent specifically to cancer cells. It is headquartered in Cambridge, Massachusetts and employs about 200 people. The company recorded revenues of $32 million during the fiscal year ended June 2006, a decrease of 10.2% compared to 2005. The operating loss of the company was $22 million during fiscal year 2006, compared to an operating loss of $13 million in 2005. The net loss was $18 million in fiscal year 2006, compared to a net loss of $11 million 2005.

Scope of the Report

- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available